Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer (NCT04671511)
Sentinel Node Biopsy and Targeted Axillary Dissection in Node-Positive Breast Cancer Patients With Clinically Negative Axilla
🩺 Plain-English Summary (8th-Grade Level)
RATIONALE: It is now standard for most breast cancer patients with 1-2 positive sentinel nodes to avoid completion node dissection when eligibility criteria from the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial are met. The National Comprehensive Cancer Network (NCCN) recently proposed to extend this indication to patients that present with biopsy proven node positive disease if only 1 or 2 suspicious nodes are found on imaging, these positive nodes are not palpable clinically, and the other eligibility criteria from the Z0011 study are otherwise met. However, this recommendation is based on an expert consensus and no study has yet confirmed the optimal method to stage the axilla in this patient population. PURPOSE: Evaluate the technical success rate and accuracy of sentinel node biopsy (SNB) and the potential benefits of clipping and removing the biopsy proven node using radioactive seed localisation (RSL) (SNB+RSL = Targeted Axillary Dissection (TAD)) in patients with biopsy proven positive nodes, limited nodal disease in imaging and clinically negative axillary examination.
Who can join: Review the eligibility criteria below.
Location: Hôpital Maisonneuve-Rosemont — Montreal, Quebec
Age range: 18 Years
🧪 Interventions in This Study
- Targeted Axillary Dissection (PROCEDURE)
- Ultrasound of the axilla (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Hôpital Maisonneuve-Rosemont — Montreal, Quebec
- Centre hospitalier de l'Université de Montréal — Montreal, Quebec
- Jewish General Hospital — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (514) 340-8222
Email: jean-francois.boileau@mcgill.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer Female
- Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer — Tampa, Florida
- Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial — Phoenix, Arizona
- Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer — Charlottesville, Virginia
- Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women — Aurora, Colorado
- Assessment of Breast Cancer Patients Satisfaction and Health Related Quality of Life Outcomes — Detroit, Michigan
- Robotic vs. Open NSM for Early Stage Breast Cancer — Irvine, California
Explore by condition: All Breast Cancer Female clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.